Imugene talks ABL partnership for VAXINIA and $80 million institutional capital raise
Imugene Limited (ASX: IMU) managing director and CEO Leslie Chong chats with Andrew Scott from Proactive about the announcement of a partnership with contract development and manufacturing organisation ABL to advance IMU’s oncolytic virus candidate towards later-phase clinical trials. Chong discusses last month’s capital raise of $80 million and three presentations Imugene will be giving […]
IN8bio progresses its novel approach to cancer therapy with gamma-delta T cell product candidates
IN8bio (NASDAQ:INAB) chief financial officer Patrick McCall takes Proactive’s Stephen Gunnion through the clinical-stage biopharmaceutical company’s novel approach to cancer therapy by advancing genetically modified gamma-delta T cells into the clinic using its DeltEx Platform. McCall also provided updates on Phase 1 clinical trials on its lead candidates, INB-100 and INB-200, and revealed that IN8bio […]